08-14 Eurofarma Laboratórios S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
05-15 Eurofarma Laboratórios S.A. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
03-26 Eurofarma Laboratórios S.A. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 CI
01-23 Bavarian Nordic A/S Signs Distribution Agreement with Eurofarma to Expand Access to Chikungunya Vaccine in Brazil CI
12-10 Psivant Therapeutics, Inc. announced that it has received $47.5 million in funding from YK Bioventures, Samsara BioCapital LLC, Roivant Sciences Ltd., LSV Capital Management, LLC, Eurofarma Laboratórios S.A. and other investors CI
11-14 Eurofarma Laboratórios S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
21/10/25 Mentis Care, Inc Appoints Hassan Kotob as Chief Executive Officer CI
21/10/25 SK Biopharmaceuticals Co., Ltd. Launches Joint Venture with Eurofarma for Ai-Based Epilepsy Management Platform CI
21/08/25 Eurofarma Laboratórios S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 CI
15/05/25 Eurofarma Laboratórios S.A. Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
26/03/25 Eurofarma Laboratórios S.A. Reports Earnings Results for the Full Year Ended December 31, 2024 CI
16/03/25 Eurofarma Laboratórios S.A. acquired 60% stake in Klibra Agenciamento de Marcas e Negócios for approximately BRL 160 million. CI
14/11/24 Eurofarma Laboratórios S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 CI
Manager TitleAgeSince
Chief Executive Officer - 22/11/2021
Investor Relations Contact 40 22/11/2021
Director TitleAgeSince
Chairman - 22/11/2021
Director/Board Member 58 22/11/2021
Director/Board Member 50 31/12/2018
Date Insider Type Main position Quantity % Market Cap. Importance
10/01/25 Buy 1,644,236 0.1665%
04/12/24 Sell 15,405,639 1.5600%
04/12/24 Buy 15,405,639 1.5600%

Financials

2024 2025
Net sales 10.97B 2.15B 1.85B 1.75B 1.59B 2.98B 205B 3B 20.84B 8.01B 105B 8.08B 7.9B 330B 12.48B 2.45B 2.11B 2B 1.81B 3.39B 234B 3.41B 23.69B 9.11B 119B 9.18B 8.98B 376B
Net income 117M 22.99M 19.8M 18.75M 17M 31.89M 2.2B 32.05M 223M 85.64M 1.12B 86.32M 84.43M 3.53B 571M 112M 96.5M 91.37M 82.82M 155M 10.7B 156M 1.09B 417M 5.44B 421M 411M 17.2B
Net Debt - -
  1. Stock Market
  2. Stocks
  3. EUFA3 Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!